P

Pfizer

Makes cancer drugs, vaccines and other medicines

Business Lead - Mkt & Sales/Commercial Bus

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's, Master's
Beijing, China+1 moreMore locations: Shanghai, China
In Person
Business & Strategy

About the job

Requirements
  • At least 15 years of experience within the pharmaceutical business, with a diverse background; a proven sales and marketing track record for a significant business or geography is preferred.
  • Fluent written and spoken English.
  • A bachelor's degree is required; a master's degree is preferred.
  • P&L management experience and financial acumen.
  • A track record of leading high-performing teams while maintaining the highest integrity.
  • Proven ability to influence a range of diverse stakeholders.
  • Strategic thinking, ability to anticipate the fast-changing healthcare environment, and an innovative mindset to embrace changes and identify innovative solutions.
  • Solid expertise in the therapeutic area and deep relationships with key opinion leaders.
  • Ability to engage, influence, and convince Global Therapeutic Area colleagues and other key stakeholders.
  • Ability to lead conversations with key stakeholders to strengthen the Therapeutic Area’s position.
Responsibilities
  • Deliver P&L results and make active trade-offs and resource-allocation decisions to optimize revenue growth through focused investments.
  • Manage expenses and investments according to plan goals, monitor business performance, and implement course-correcting actions.
  • Own the end-to-end portfolio, including organic and inorganic pipeline planning, new product launches, and commercialization.
  • Build the business as a future growth engine for Pfizer China, enter new disease areas, develop the market, address accessibility and affordability challenges, and establish Pfizer as a leader in China.
  • Lead and coach the Marketing and Sales functions to drive cohesive business-unit operations from strategy through implementation.
  • Lead and coach Commercial Development to develop portfolio strategy and planning suited to China, work with Development China and Regulatory Affairs to accelerate the pipeline, and identify opportunities for early launch where possible.
  • Drive strategic portfolio planning and collaborate with internal stakeholders to accelerate the pipeline and explore innovative pathways.
  • Build alignment across functions and management layers locally, in Emerging Markets, and at headquarters to advocate for China priorities and secure sufficient pipeline investment for future growth.
  • Set the long-term vision and develop category-specific strategies to maximize patient impact and revenue.
  • Drive innovation to maximize patient reach and address unmet needs.
  • Ensure launch readiness for new products and indications through robust launch strategy development and market preparedness.
  • Drive campaigns, plans of action, tactics, customer plans, and successful launch execution for key brands in the category.
  • Optimize business performance and manage daily operations.
  • Review, design, and monitor Sales Team effectiveness through SMART key performance indicators.
  • Engage and influence internal stakeholders to advocate for business priorities, align cross-functional and cross-layer support to business needs, and obtain leadership buy-in.
  • Lead discussions with external stakeholders, including key opinion leaders and government representatives, to enhance disease awareness and deepen Pfizer China’s engagement and influence in the ecosystem.
  • Lead and coach a high-performing team and develop colleagues in line with Pfizer competency models.
  • Ensure compliance with norms, policies, and procedures, and instill proactive compliance risk management throughout the direct team and cross-functional organization.
  • Conduct activities in accordance with company policies and standard operating procedures, Pfizer values, and applicable global guidelines, including MAPP and FCPA.
  • Represent Pfizer and engage external stakeholders, including government officials, industry associations, key opinion leaders, customers, and media; communicate Pfizer’s value and help build the patient ecosystem.
  • Contribute as a key member of the Pfizer China leadership team to Pfizer China’s overall success.
Desired Qualifications
  • A proven sales and marketing track record for a significant business or geography.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.